49679-45-0

Basic information

• Product Name: ETHYL 3-CHLOROQUINOXALINE-2-CARBOXYLATE
• Synonyms: ETHYL 3-CHLOROQUINOXALINE-2-CARBOXYLATE;3-Chloroquinoxaline-2-carboxylic acid ethyl ester
• CAS NO: 49679-45-0
• Molecular Formula: C₁₁H₉ClN₂O₂
• Molecular Weight: 236.66
• Mol File: 49679-45-0.mol

Chemical Properties

• Melting Point: 41-42℃
• Boiling Point: 330.7 °C at 760 mmHg
• Flash Point: 153.8 °C
• Appearance: /
• Density: 1.341
• Vapor Pressure: 0.000163mmHg at 25°C
• Refractive Index: 1.615
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -5.14±0.48(Predicted)
• CAS DataBase Reference: ETHYL 3-CHLOROQUINOXALINE-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3-CHLOROQUINOXALINE-2-CARBOXYLATE(49679-45-0)
• EPA Substance Registry System: ETHYL 3-CHLOROQUINOXALINE-2-CARBOXYLATE(49679-45-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 49679-45-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
ETHYL 3-CHLOROQUINOXALINE-2-CARBOXYLATE is used as an intermediate in the synthesis of pharmaceuticals for its reactivity and potential to contribute to the development of new drugs.
Used in Agrochemical Development:
In the agrochemical industry, ETHYL 3-CHLOROQUINOXALINE-2-CARBOXYLATE is used as a precursor in the creation of agrochemicals, potentially enhancing crop protection and yield through its incorporation into various formulations.
Used in Medicinal Chemistry Research:
ETHYL 3-CHLOROQUINOXALINE-2-CARBOXYLATE serves as a subject of study in medicinal chemistry, where its structure and properties are investigated for potential therapeutic applications and to understand its interactions with biological systems.
Used in Pharmacology:
In pharmacology, ETHYL 3-CHLOROQUINOXALINE-2-CARBOXYLATE is utilized for exploring its effects on biological targets, which may lead to the discovery of new mechanisms of action and therapeutic potentials.

InChI:InChI=1/C11H9ClN2O2/c1-2-16-11(15)9-10(12)14-8-6-4-3-5-7(8)13-9/h3-6H,2H2,1H3

Upstream product

• 23395-75-7 ethyl 2-quinoxalinecarboxylate 4-oxide 
• 105-53-3 diethyl malonate 
• 95-54-5 1,2-diamino-benzene 
• 609-09-6 Diethyl ketomalonate 
• 685-87-0 Diethyl 2-bromomalonate 
• 36818-08-3 ethyl 1,2,3,4-tetrahydro-3-oxoquinoxaline-2-carboxylate 
• 7065-23-8 ethyl quinoxaline-2-carboxylate 
• 36818-07-2 ethyl-3-hydroxy-quinoxaline-2-carboxylate 
• 36818-07-2 ethyl 3-oxo-4H-quinoxaline-2-carboxylate 

Downstream Products

• 20254-76-6 3-Chloroquinoxaline-2-carboxylic acid 
• 67568-30-3 2-Amino-3-carboxamidoquinoxaline 
• 154371-12-7 4-oxo-2-(p-tolylamino)<1,3>thiazino<5,6-b>quinoxaline 
• 154371-18-3 2-(3-Chloro-phenylamino)-1-thia-3,9,10-triaza-anthracen-4-one 
• 154371-19-4 2-(4-Bromo-phenylamino)-1-thia-3,9,10-triaza-anthracen-4-one 
• 154371-23-0 2-(2,4-Dimethyl-phenylamino)-1-thia-3,9,10-triaza-anthracen-4-one 
• 476374-05-7 3-(4-ethoxycarbonylmethyl-phenylamino)-quinoxaline-2-carboxylic acid ethyl ester 
• 1448-87-9 2-chloroquinoxaline 

Relevant articles and documents

Design and synthesis of a novel mitochondria-targeted osteosarcoma theranostic agent based on a PIM1 kinase inhibitor

Osteosarcoma (OS) is the most common malignancy of the skeletal system, with a poor prognosis and high rate of recurrence. Adequate surgical margin and adjuvant chemotherapy improve the overall survival and limb salvage rate of osteosarcoma patients. Previous studies have showed that OS exhibits an increase in the expression of proviral integration site for Moloney murine leukemia virus 1 (PIM1) kinase, and high levels of PIM1 are also associated with poor OS prognosis and metastasis. We exploited the overexpression of proto-oncogenic PIM1 in OS towards the development of a novel near-infrared imaging and targeted therapeutic agent, namely QCAi-Cy7d by conjugating a PIM1 small molecule inhibitor and heptamethine cyanine dye, for simultaneous guiding surgery and chemotherapy. QCAi-Cy7d showed targeted imaging and anticancer activities against OS in vitro and vivo without any obvious toxicity, and its antitumoral activity was much greater than the parent PIMI inhibitor. These results demonstrated the potential of new conjugate of PIM1 inhibitor and near-infrared imaging, supporting structure-based design and development of theranostic agents for precise tumor imaging and targeted treatment.

3-Arylamino-quinoxaline-2-carboxamides inhibit the PI3K/Akt/mTOR signaling pathways to activate P53 and induce apoptosis

Thirty-eight new 3-arylaminoquinoxaline-2-carboxamide derivatives were in silico designed, synthesized and their cytotoxicity against five human cancer cell lines and one normal cells WI-38 were evaluated. Molecular mechanism studies indicated that N-(3-A

3-aryl amine quinoxalin-2-formamide derivative as well as preparation method and application thereof

The invention relates to a 3-aryl amine quinoxalin-2-formamide derivative as well as a preparation method and application thereof. The 3-aryl amine quinoxalin-2-formamide derivative is synthesized byusing a simple and convenient method, the yield is high,

Quinoxaline signal pathway inhibitors as well as preparation method and application thereof

The invention belongs to the technical field of pharmaceutical chemistry, and particularly provides quinoxaline signal pathway inhibitors and a preparation method and application thereof. The generalformula of the quinoxaline signal pathway inhibitor is s

Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors

We identified a new series of quinoxaline-2-carboxylic acid derivatives, targeting the human proviral integration site for Moloney murine leukemia virus-1 (HsPim-1) kinase. Seventeen analogues were synthesized providing useful insight into structure-activity relationships studied. Docking studies realized in the ATP pocket of HsPim-1 are consistent with an unclassical binding mode of these inhibitors. The lead compound 1 was able to block HsPim-1 enzymatic activity at nanomolar concentrations (IC50 of 74 nM), with a good selectivity profile against a panel of mammalian protein kinases. In vitro studies on the human chronic myeloid leukemia cell line KU812 showed an antitumor activity at micromolar concentrations. As a result, compound 1 represents a promising lead for the design of novel anticancer targeted therapies.

Synthesis of 2-(Quinoxalin-2-ylamino-benzotriazolyl) Pentanedioic Derivatives as Potential Anti-Folate Agents

Anti-folate agents had a significant impact on therapeutic treatment plans for diseases such as cancer, and bacterial and parasitic infections, notably malaria. Quinoxaline derivatives showed in vitro anticancer activity and were able to inhibit both the dihydrofolate reductase and thymidylate synthase. Here, we decided to combine the chemical properties of quinoxalines and quinoxaline 1,4-dioxides with those of benzotriazole nucleus with the aim to evaluate the resulting biological properties. Two main new series, including more than 60 compounds, were prepared. In the first one, the benzotriazole moiety was linked through the nitrogen atoms 1, 2, or 3, to a glutaric acid substituent to simulate a glutamic moiety. In the second series, the glutaric acid was substituted with acetic acid moiety to evaluate the effects of steric hindrance. Here, we describe the multistep chemical processes to obtain all titled quinoxalines starting from commercially available diamines. The classical oxidation of selected quinoxalines was unsuccessful, and we have come to an independent synthetic pathway to obtain new derivatives linked to the benzotriazole moieties starting from synthons bearing N-oxide functionality.

Ligand-based design, synthesis, and pharmacological evaluation of 3-methoxyquinoxalin-2-carboxamides as structurally novel serotonin type-3 receptor antagonists

Employing a ligand-based approach, 3-methoxyquinoxalin-2-carboxamides were designed as serotonin type-3 (5-HT3) receptor antagonists and synthesized from the starting material o-phenylenediamine in a sequence of reactions. The structures of the

Discovery of new anti-depressants from structurally novel 5-HT3 receptor antagonists: Design, synthesis and pharmacological evaluation of 3-ethoxyquinoxalin-2-carboxamides

A novel series of 3-ethoxyquinoxalin-2-carboxamides were designed as per the pharmacophoric requirements of 5-HT3 receptor antagonist using ligand-based approach. The desired carboxamides were synthesized from the key intermediate, 3-ethoxyquin

Pyrazolo[4′,3′:5,6]pyrano[2,3-b]quinoxalin-4(1H)-one: Synthesis and characterization of a novel tetracyclic ring system

(Chemical Equation Presented) Derivatives of the hitherto unknown ring system, pyrazolo[4′,3′:5,6]pyrano[2,3-b]quinoxalin-4(1H)-one, are synthesized in one step from the corresponding 1-substuituted or 1,3-disubstituted 2-pyrazolin-5-ones and 3-chloroquinoxaline-2-carbonyl chloride using calcium hydroxide in boiling 1,4-dioxane. The parent system carrying no substituent in positions 1 and 3 is obtained upon treatment of the 1-PMB (p-methoxybenzyl) protected congener with trifluoroacetic acid. Detailed NMR spectroscopic investigations including unambiguous chemical shift assignments of all 1H, 13C, and 15N resonances of the obtained tetracycles are reported.

QUINOXALINES USEFUL AS INHIBITORS OF PROTEIN KINASES

The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, c